RU2018134061A - Лираглутид при сердечно-сосудистых состояниях - Google Patents
Лираглутид при сердечно-сосудистых состояниях Download PDFInfo
- Publication number
- RU2018134061A RU2018134061A RU2018134061A RU2018134061A RU2018134061A RU 2018134061 A RU2018134061 A RU 2018134061A RU 2018134061 A RU2018134061 A RU 2018134061A RU 2018134061 A RU2018134061 A RU 2018134061A RU 2018134061 A RU2018134061 A RU 2018134061A
- Authority
- RU
- Russia
- Prior art keywords
- paragraphs
- subject
- cardiovascular
- group
- left ventricular
- Prior art date
Links
- 230000002526 effect on cardiovascular system Effects 0.000 title claims 4
- 238000000034 method Methods 0.000 claims 13
- 231100001160 nonlethal Toxicity 0.000 claims 6
- 208000024172 Cardiovascular disease Diseases 0.000 claims 4
- 208000019553 vascular disease Diseases 0.000 claims 4
- 208000010125 myocardial infarction Diseases 0.000 claims 3
- 230000007170 pathology Effects 0.000 claims 3
- 206010007558 Cardiac failure chronic Diseases 0.000 claims 2
- 206010052337 Diastolic dysfunction Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 206010049694 Left Ventricular Dysfunction Diseases 0.000 claims 2
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 claims 2
- YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 claims 2
- 108010019598 Liraglutide Proteins 0.000 claims 2
- 206010027525 Microalbuminuria Diseases 0.000 claims 2
- 230000002411 adverse Effects 0.000 claims 2
- 230000007211 cardiovascular event Effects 0.000 claims 2
- 238000002651 drug therapy Methods 0.000 claims 2
- 229960002701 liraglutide Drugs 0.000 claims 2
- 201000001474 proteinuria Diseases 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 230000002861 ventricular Effects 0.000 claims 2
- 206010002388 Angina unstable Diseases 0.000 claims 1
- 208000018262 Peripheral vascular disease Diseases 0.000 claims 1
- 206010062237 Renal impairment Diseases 0.000 claims 1
- 208000007814 Unstable Angina Diseases 0.000 claims 1
- 208000026106 cerebrovascular disease Diseases 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims 1
- 230000000250 revascularization Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Claims (19)
1. Способ уменьшения развития серьезного нежелательного сердечно-сосудистого явления (МАСЕ), включающий
введение лираглутида в терапевтически эффективном количестве субъекту, нуждающемуся в этом,
при этом субъект имеет диабет 2 типа и один или более факторов риска сосудистого заболевания.
2. Способ по п. 1, где МАСЕ выбрано из группы, состоящей из смерти по причине сердечно-сосудистой патологии, из нелетального инфаркта миокарда, нелетального инсульта, коронарной реваскуляризации, госпитализации по причине нестабильной стенокардии и госпитализации по причине хронической сердечной недостаточности.
3. Способ по п. 1 или 2, где МАСЕ выбрано из группы, состоящей из смерти по причине сердечно-сосудистой патологии, из нелетального инфаркта миокарда и нелетального инсульта.
4. Способ по любому из пп. 1-3, где сосудистое заболевание выбрано из группы, состоящей из сердечно-сосудистого заболевания, нарушения мозгового кровообращения, заболевания периферических сосудов, хронической почечной недостаточности и хронической сердечной недостаточности.
5. Способ по любому из пп. 1-4, где сосудистое заболевание представляет собой сердечно-сосудистое заболевание.
6. Способ по любому из пп. 1-5, где один или более факторов риска выбраны из группы, состоящей из микроальбуминурии, протеинурии, гипертензии, гипертрофии левого желудочка, систолической дисфункции левого желудочка, диастолической дисфункции левого желудочка и лодыжечно-брахиального индекса <0,9.
7. Способ по любому из пп. 1-6, где субъект уже получает лекарственную терапию сердечно-сосудистых заболеваний.
8. Способ уменьшения развития серьезного нежелательного сердечно-сосудистого явления (МАСЕ), включающий
введение лираглутида в терапевтически эффективном количестве субъекту, нуждающемуся в этом,
при этом субъект имеет диабет 2 типа и один или более факторов риска сосудистого заболевания.
при этом субъект уже получает лекарственную терапию сердечно-сосудистых заболеваний, и
при этом МАСЕ выбрано из группы, состоящей из смерти по причине сердечно-сосудистой патологии, из нелетального инфаркта миокарда и нелетального инсульта.
9. Способ по любому из пп. 1-8, где один или более факторов риска выбраны из группы, состоящей из микроальбуминурии, протеинурии, гипертензии, гипертрофии левого желудочка, систолической дисфункции левого желудочка, диастолической дисфункции левого желудочка и лодыжечно-брахиального индекса <0,9.
10. Способ по любому из пп. 1-9, где возраст субъекта составляет по меньшей мере 60 лет.
11. Способ по любому из пп. 1-10, где указанный субъект имеет BMI выше 30 кг/м2, например, BMI по меньшей мере 30,4 кг/м2.
12. Способ по любому из пп. 1-11, где указанный субъект имеет уровень НbА1с выше 8,3%, например, уровень НbА1с по меньшей мере 8,4% или по меньшей мере 9,0%.
13. Способ по любому из пп. 1-12, где указанный субъект имеет умеренное нарушение функции почек.
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16158739.9 | 2016-03-04 | ||
| EP16158739 | 2016-03-04 | ||
| EP16173917.2 | 2016-06-10 | ||
| EP16173917 | 2016-06-10 | ||
| EP16001329.8 | 2016-06-13 | ||
| EP16001329 | 2016-06-13 | ||
| US15/401,651 | 2017-01-09 | ||
| US15/401,651 US9968659B2 (en) | 2016-03-04 | 2017-01-09 | Liraglutide in cardiovascular conditions |
| PCT/EP2017/054990 WO2017149112A1 (en) | 2016-03-04 | 2017-03-03 | Liraglutide in cardiovascular conditions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2018134061A true RU2018134061A (ru) | 2020-04-06 |
| RU2018134061A3 RU2018134061A3 (ru) | 2020-07-15 |
| RU2745604C2 RU2745604C2 (ru) | 2021-03-29 |
Family
ID=59723004
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018134061A RU2745604C2 (ru) | 2016-03-04 | 2017-03-03 | Лираглутид при сердечно-сосудистых состояниях |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US9968659B2 (ru) |
| EP (1) | EP3423082B1 (ru) |
| JP (1) | JP6940512B2 (ru) |
| KR (1) | KR102417455B1 (ru) |
| CN (2) | CN116327897A (ru) |
| AU (2) | AU2017225841A1 (ru) |
| BR (1) | BR112018067344A2 (ru) |
| CA (1) | CA3013532C (ru) |
| CL (1) | CL2018002515A1 (ru) |
| DK (1) | DK3423082T5 (ru) |
| ES (1) | ES2893755T3 (ru) |
| HR (1) | HRP20211492T1 (ru) |
| HU (1) | HUE055844T2 (ru) |
| IL (1) | IL261169B (ru) |
| MA (1) | MA43704A (ru) |
| MX (1) | MX394179B (ru) |
| MY (1) | MY195657A (ru) |
| PH (1) | PH12018501844B1 (ru) |
| PL (1) | PL3423082T3 (ru) |
| RS (1) | RS62501B1 (ru) |
| RU (1) | RU2745604C2 (ru) |
| SI (1) | SI3423082T1 (ru) |
| WO (1) | WO2017149112A1 (ru) |
| ZA (1) | ZA201805538B (ru) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9968659B2 (en) | 2016-03-04 | 2018-05-15 | Novo Nordisk A/S | Liraglutide in cardiovascular conditions |
| CA3056663C (en) | 2019-04-05 | 2022-10-18 | Jeffrey S. RIESMEYER | Use of dulaglutide in reducing risk of cardiovascular events in patients with type 2 diabetes mellitus |
| JP2024500410A (ja) * | 2020-12-16 | 2024-01-09 | ザ チャイニーズ ユニバーシティー オブ ホンコン | 老化脳機能低下を逆転する方法 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5808203A (en) | 1997-05-12 | 1998-09-15 | Medrad, Inc. | Fluid pressure measurement devices |
| WO2003084563A1 (en) * | 2002-04-04 | 2003-10-16 | Novo Nordisk A/S | Glp-1 agonist and cardiovascular complications |
| CN102784386A (zh) * | 2003-11-20 | 2012-11-21 | 诺沃挪第克公司 | 对于生产和用于注射装置中是最佳的含有丙二醇的肽制剂 |
| CN112618700A (zh) * | 2004-11-12 | 2021-04-09 | 诺和诺德公司 | 促胰岛素肽的稳定制剂 |
| EP2190872B1 (en) * | 2007-09-05 | 2018-03-14 | Novo Nordisk A/S | Glucagon-like peptide-1 derivatives and their pharmaceutical use |
| UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
| AR074990A1 (es) | 2009-01-07 | 2011-03-02 | Boehringer Ingelheim Int | Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina |
| AR075204A1 (es) | 2009-01-29 | 2011-03-16 | Boehringer Ingelheim Int | Inhibidores de dpp-4 y composiciones farmaceuticas que los comprenden, utiles para tratar enfermedades metabolicas en pacientes pediatricos, particularmente diabetes mellitus tipo 2 |
| BRPI1013500A2 (pt) | 2009-03-27 | 2016-04-05 | Astrazeneca Uk Ltd | métodos para previnir eventos cardiovasculares adversos maiores com inibidores de dpp-iv |
| WO2011140176A1 (en) | 2010-05-04 | 2011-11-10 | Glaxosmithkline Llc | Methods for treating or preventing cardiovascular disorders and providing cardiovascular protection |
| ES2802243T3 (es) | 2010-06-24 | 2021-01-18 | Boehringer Ingelheim Int | Terapia para la diabetes |
| AR083878A1 (es) | 2010-11-15 | 2013-03-27 | Boehringer Ingelheim Int | Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento |
| US20130172244A1 (en) | 2011-12-29 | 2013-07-04 | Thomas Klein | Subcutaneous therapeutic use of dpp-4 inhibitor |
| US20130303462A1 (en) | 2012-05-14 | 2013-11-14 | Boehringer Ingelheim International Gmbh | Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome |
| EP4151218A1 (en) | 2012-05-14 | 2023-03-22 | Boehringer Ingelheim International GmbH | Linagliptin, a xanthine derivative as dpp-4 inhibitor, for use in the treatment of sirs and/or sepsis |
| JP6374862B2 (ja) | 2012-05-24 | 2018-08-15 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 自己免疫性糖尿病、特に、ｌａｄａの治療に使用するためのｄｐｐ−４阻害剤としてのキサンチン誘導体 |
| CN103893744B (zh) * | 2012-12-24 | 2017-12-19 | 杭州九源基因工程有限公司 | 一种治疗糖尿病的药物制剂及其制备方法 |
| AU2014230096C1 (en) | 2013-03-15 | 2019-08-29 | Boehringer Ingelheim International Gmbh | Use of linagliptin in cardio- and renoprotective antidiabetic therapy |
| CA2914791A1 (en) | 2013-06-14 | 2014-12-18 | Boehringer Ingelheim International Gmbh | Dpp-4 inhibitors for treating diabetes and its complications |
| US8969371B1 (en) | 2013-12-06 | 2015-03-03 | Orexigen Therapeutics, Inc. | Compositions and methods for weight loss in at risk patient populations |
| ES2950384T3 (es) | 2014-02-28 | 2023-10-09 | Boehringer Ingelheim Int | Uso médico de un inhibidor de DPP-4 |
| WO2016019587A1 (en) | 2014-08-08 | 2016-02-11 | Merck Sharp & Dohme Corp. | [7, 6]-fused bicyclic antidiabetic compounds |
| US9968659B2 (en) | 2016-03-04 | 2018-05-15 | Novo Nordisk A/S | Liraglutide in cardiovascular conditions |
-
2017
- 2017-01-09 US US15/401,651 patent/US9968659B2/en active Active
- 2017-03-03 PH PH1/2018/501844A patent/PH12018501844B1/en unknown
- 2017-03-03 SI SI201730917T patent/SI3423082T1/sl unknown
- 2017-03-03 KR KR1020187026962A patent/KR102417455B1/ko active Active
- 2017-03-03 DK DK17710160.7T patent/DK3423082T5/da active
- 2017-03-03 WO PCT/EP2017/054990 patent/WO2017149112A1/en not_active Ceased
- 2017-03-03 CA CA3013532A patent/CA3013532C/en not_active Expired - Fee Related
- 2017-03-03 CN CN202310320736.6A patent/CN116327897A/zh active Pending
- 2017-03-03 BR BR112018067344A patent/BR112018067344A2/pt unknown
- 2017-03-03 PL PL17710160T patent/PL3423082T3/pl unknown
- 2017-03-03 AU AU2017225841A patent/AU2017225841A1/en not_active Abandoned
- 2017-03-03 MA MA043704A patent/MA43704A/fr unknown
- 2017-03-03 JP JP2018546477A patent/JP6940512B2/ja active Active
- 2017-03-03 ES ES17710160T patent/ES2893755T3/es active Active
- 2017-03-03 MY MYPI2018702782A patent/MY195657A/en unknown
- 2017-03-03 CN CN201780015266.5A patent/CN108778317A/zh active Pending
- 2017-03-03 MX MX2018010097A patent/MX394179B/es unknown
- 2017-03-03 HU HUE17710160A patent/HUE055844T2/hu unknown
- 2017-03-03 HR HRP20211492TT patent/HRP20211492T1/hr unknown
- 2017-03-03 EP EP17710160.7A patent/EP3423082B1/en active Active
- 2017-03-03 RS RS20211250A patent/RS62501B1/sr unknown
- 2017-03-03 RU RU2018134061A patent/RU2745604C2/ru active
-
2018
- 2018-04-18 US US15/956,445 patent/US20180236038A1/en not_active Abandoned
- 2018-08-15 IL IL26116918A patent/IL261169B/en unknown
- 2018-08-20 ZA ZA2018/05538A patent/ZA201805538B/en unknown
- 2018-09-03 CL CL2018002515A patent/CL2018002515A1/es unknown
-
2024
- 2024-03-26 AU AU2024201937A patent/AU2024201937A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Camm et al. | The increasing role of rhythm control in patients with atrial fibrillation: JACC state-of-the-art review | |
| Filippatos et al. | SGLT2 inhibitors and cardioprotection: a matter of debate and multiple hypotheses | |
| Koniari et al. | Pharmacologic prophylaxis for atrial fibrillation following cardiac surgery: a systematic review | |
| RU2018134061A (ru) | Лираглутид при сердечно-сосудистых состояниях | |
| Grassi et al. | Hyperuricemia and cardiovascular risk | |
| Sibley et al. | New‐onset atrial fibrillation in critically ill patients | |
| RU2008150477A (ru) | Фармацевтическая композиция, содержащая амлодипин и лозартан | |
| JP2019206562A5 (ru) | ||
| Kuriyama | Protection of the kidney with sodium–glucose cotransporter 2 inhibitors: potential mechanisms raised by the large-scaled randomized control trials | |
| Basso et al. | The metamorphosis of myocardial infarction following coronary recanalization | |
| Capucci et al. | Emerging pharmacotherapies for the treatment of atrial fibrillation | |
| Barman | Proarrhythmic effects of antiarrhythmic drugs: case study of flecainide induced ventricular arrhythmias during treatment of atrial fibrillation | |
| JP2019535785A5 (ru) | ||
| JP2020502155A5 (ru) | ||
| Naranjo et al. | Cardio-Renal Syndrome: A double edged sword | |
| ME03791B (me) | Derivat triazolopirazinona koristan kao inhibitor ljudskog pde1 | |
| Alagiakrishnan et al. | Medication management of chronic heart failure in older adults | |
| Feng et al. | Emerging horizons: clinical applications and multifaceted benefits of SGLT-2 inhibitors beyond diabetes | |
| Liu et al. | Zhen-Wu decoction and lactiflorin, an ingredient predicted by in silico modelling, alleviate uremia induced cardiac endothelial injury via Nrf2 activation | |
| Vega et al. | New oral anticoagulants in patients with chronic kidney disease | |
| EA202191150A1 (ru) | Ингибиторы аминопептидазы а и содержащие их фармацевтические композиции | |
| EP2905022B1 (en) | Pharmaceutical composition of 1-adamantylethyloxy-3-morpholino-2-propanol or pharmaceutically acceptable salts thereof for the treatment of cardiovascular disease | |
| Filippi-Codaccioni et al. | Relation between the A1166C angiotensin II type 1 receptor gene polymorphism and cardiovascular outcomes after myocardial infarction | |
| Shalaeva et al. | Administration of loading doses of statins for prevention of contrast-induced kidney injury during endovascular interventions in patients with ischemic heart disease | |
| Obeng-Gyimah et al. | Cardiorenal resynchronization therapy: strengthening the heart and kidneys |